drugset / Trial / NCT07128472

Evaluation of IL 12B Genetic Polymorphism (rs3213094)

NCT07128472

Recruiting 40 enrolled South Valley University
RandomizedParallel-groupOpen-labelTreatment

Summary

Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.

Timeline

Start
2025-08-01
Primary completion
2026-01-20
Completion
2026-02-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody

Indications